title: Phase I study of 4'-deoxydoxorubicin (esorubicin) in children with malignant solid tumors.
abstract: 4'-Deoxydoxorubicin was given to 15 patients with drug-resistant pediatric malignant solid tumors with the objectives of determining the maximum tolerated dosage and dose-limiting toxicity. Maximum tolerated dosage was 36 mg/m2 given IV once every 3 weeks. Dose limiting toxicity was myelosuppression, which was severe and prolonged. Therapeutic benefits were not observed for these patients.
authors: Department of Hematology-Oncology, St. Jude Children's Research Hospital, Memphis, TN 38101.
authors: C B
authors: CB
authors: Pratt
authors: E C
authors: EC
authors: Douglass
authors: W H
authors: WH
authors: Meyer
authors: F A
authors: FA
authors: Hayes
authors: M E
authors: ME
authors: Horowitz
authors: E I
authors: EI
authors: Thompson
authors: L
authors: L
authors: Avery
mesh_terms: D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004341:Drug Evaluation; D005260:Female; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D004317:Doxorubicin; C030851:esorubicin